✦ LIBER ✦

A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson's disease

✍ Scribed by V. Nohria; A. Partiot

Book ID: 111063968
Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 671 KB
Volume: 4
Category: Article
ISSN: 1351-5101
DOI: 10.1111/j.1468-1331.1997.tb00403.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dopamine receptor agonists in the treatm

Dopamine receptor agonists in the treatment of advanced Parkinson's disease

✍ Fabrizio Stocchi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Dopamine agonist-based strategies in the

Dopamine agonist-based strategies in the treatment of Parkinson’s disease

✍ Angelo Antonini; Paolo Barone 📂 Article 📅 2008 🏛 Springer Milan 🌐 English ⚖ 112 KB

Dopamine agonists in the treatment of ea

Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis

✍ William L. Baker; Dee Silver; C. Michael White; Jeffrey Kluger; Jeffrey Aberle; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Bromocriptine (parlodelR) in the treatme

Bromocriptine (parlodelR) in the treatment of parkinson's disease

✍ Molina-Negro, Pedro; Grimes, J. David; Jones, Michael W.; Kofman, Oscar S.; Bouc 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Pramipexole — a new dopamine agonist for

Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease

✍ James P Bennett Jr.; Montford F Piercey 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 121 KB

A “combined” levodopa test as a useful m

A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

✍ Dr. A. M. Bonnet; I. Serre; R. Marconi; Y. Agid; B. Dubois 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 1 views

## Abstract The efficacy of pergolide as adjunct to levodopa therapy was compared to that of bromocriptine in 12 parkinsonian patients with fluctuating motor disability and levodopa‐induced dyskinesias (mean age of onset, 50.6 ± 8 years; Hoehn and Yahr stage between II and IV; mean basal UPDRS moto